Company Profile

Sunniva is an ancient English name which means "Gift of the Sun."

Strategic assets are in place to become one of the lowest cost, high margin operators, producing pesticide-free premium quality cannabis, and achieving vertical integration in California through:

  • Leveraging our large-scale, purpose-built high technology cGMP designed glasshouse (currently under construction)
  • Highly experienced management team assembled in California
  • A Board of Directors with a proven track record for creating significant shareholder value both in the healthcare and biotech industries

“Our team is committed to cultivating and manufacturing safe, high-quality cannabis and services at scale. We will achieve this by attracting better talent, embracing better standards, and implementing better business practices.”

—

Dr. Anthony (Tony) Holler, Founder and CEO

Better Leadership

Sunniva’s Management Team

Dr. Anthony Holler

Chairman and CEO

Dr. Anthony (Tony) Holler is the former CEO and co-founder of ID Biomedical, acquired in 2015 by Glaxo Smith Kline for $1.7 billion, and former Chairman of Corriente Resources Inc., sold for approximately $700 million to CRCC-Tongguan Investment Co. Tony is the current Chairman of CRH Medical Corp., a publicly traded company and serves as Sunniva’s Chief Executive Officer. His expertise includes strategic planning, mergers and acquisitions, and financing, with a singular focus on increasing shareholder value.

David Weinmann

Interim Chief Financial Officer

David Weinmann joined Sunniva in June 2019 as Global Controller.  In addition to the oversight of the accounting functions of Sunniva, as the Interim Chief Financial Officer role he will also be responsible for the administrative, financial and risk management operations of the Company.  David has over 20 years of progressively increasing experience in both public and privately held companies with the majority of his career in the biotech and pharmaceutical industries.  Prior to joining Sunniva, he worked for Thermo Fisher Scientific, Inc., Accriva Diagnostics, and Ambit Biosciences.  He has spent the past few years consulting for companies within the start up, transition, and transaction phase, including, ACEA Biosciences, Inc., Ametek, Inc., and Robo3D Limited. Mr. Weinmann has a Bachelor of Science in Accountancy from San Diego State University.

Better Governance

Sunniva’s Board Of Directors

Dr. Anthony Holler

Chairman and CEO

Dr. Anthony (Tony) Holler is the former CEO and co-founder of ID Biomedical, acquired in 2015 by Glaxo Smith Kline for $1.7 billion, and former Chairman of Corriente Resources Inc., sold for approximately $700 million to CRCC-Tongguan Investment Co. Tony is the current Chairman of CRH Medical Corp., a publicly traded company and serves as Sunniva’s Chief Executive Officer. His expertise includes strategic planning, mergers and acquisitions, and financing, with a singular focus on increasing shareholder value.

Norm Mayr

Director (Independent)

Norm Mayr is a recently retired (2016) Audit Partner having spent 38 years in public practice with KPMG. He was the Risk Management and Professional Practice Partner for the Greater Vancouver Area practice of KPMG for the most recent 18 years of his career. In this role, Norm was consulted regularly on complex financial reporting, accounting, audit, and securities issues. Norm has extensive experience in the mining, forestry, technology, retail and industrial markets sectors and he served as lead partner on many of KPMG’s largest multinational clients in these industries. He was a founding member of the CICA Accounting Standards Board and a member of the Canadian Advisory Group to the International Accounting Standards Committee.

Ian Webb

Director (Independent)

Former director of ID Biomedical and current director of CRH Medical Corp. Also, former senior corporate law partner of Borden Ladner Gervais LLP, one of Canada’s largest law firms, whose practice encompassed mergers and acquisitions as well as corporate and securities law with an emphasis on the legal requirements of public companies and their boards.